undamentalytics Newsletter
Sign in

Vericel Corp income statement

In fiscal 2025, Vericel Corp reported revenue of $276m, up 16.5% on the year before, operating income of $11.0m (a 4.0% margin) and net income of $16.5m, or $0.32 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Jun 20092010Jun 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue000002951546491118124156164198237276306
Cost of revenue———————2830323840505562657178
Gross profit———0012252634598084106110136172206228
Research and development111321261521191513143013162021252829
Selling, general and administrative558861422273649616998107121143167181
Operating income−16−18−29−34−21−24−17−19−15−4−112−8−17−651118
Interest expense000000000000001111
Income before tax—−15−20−29−16−20−16−20−17−8−103−8−16−21117—
Income tax————00000000−01101—
Net income−16−15−20−29−16−20−16−20−17−8−103−7−17−3101724
Diluted EPS−$2.25−$0.07−$1.27−$2.03−$0.87−$1.11−$0.97−$1.18−$0.52−$0.20−$0.22$0.06−$0.16−$0.35−$0.07$0.20$0.32$0.46
Diluted shares (average)7m10m15m16m24m23m24m23m33m40m44m47m46m47m48m52m52m53m
EBITDA−15−17−28−33−20−23−15−17−13−2−105−5−13−2102331

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ADPT vs VCELVCEL vs VIRARVN vs VCELIOVA vs VCEL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vericel Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vericel Corp.